Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 267-273

  Lo, Chyi ^a,b   Lai, Tung Yuan ^c,g   Yang, Jai Sing ^d   Yang, Jen Hung ^h,i   Ma, Yi Shih ^a   Weng, Shu Wen ^a   Lin, Hui Yi ^e   Chen, Hung Yi ^e   Lin, Jaung Geng ^a   Chung, Jing Gung ^f,j  

^a School of Chinese Medicine   (Taiwan)

^b Chang Gung University of Science and Technology at Chiayi Campus   (Taiwan)

^c School of Post Baccalaureate Chinese Medicine   (Taiwan)

^d Department of Pharmacology ^*  (Taiwan)

^e School of Pharmacy   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^j ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

A375.S2 melanoma cells; gallic acid; invasion; matrix metalloproteinases; migration

Indexed keywords

ANTIMETASTATIC AGENT; GALLIC ACID; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPIDIUM IODIDE; PROTEIN KINASE B; RAS PROTEIN; RHO KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; GALLIC ACID; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MELANOMA; NEOPLASM INVASIVENESS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS;

EID: 79960707329     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283414444     Document Type: Article

References (38)

1. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008; 624:89-103.
2. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9.
3. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004; 4:23-35. (Pubitemid 38082151)
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81:500-507.
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841. (Pubitemid 29108856)
6. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007; 99:777-789. (Pubitemid 47073524)
7. Rahman M, Sakamoto J, Fukui T. Calculation of population attributable risk for bidi smoking and oral cancer in south Asia. Prev Med 2005; 40:510-514. (Pubitemid 40320716)
8. Meyskens FL Jr, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 2005; 14:1366-1369. (Pubitemid 40807332)
9. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. I. Epidemiology. Cancer Causes Control 1991; 2:325-357.
10. Manna SK, Kuo MT, Aggarwal BB. Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1. Oncogene 1999; 18:4371-4382. (Pubitemid 29392378)
11. Klein E, Weber N. In vitro test for the effectiveness of antioxidants as inhibitors of thiyl radical-induced reactions with unsaturated fatty acids. J Agric Food Chem 2001; 49:1224-1227. (Pubitemid 32884938)
12. Grundhofer P, Niemetz R, Schilling G, Gross GG. Biosynthesis and subcellular distribution of hydrolyzable tannins. Phytochemistry 2001; 57:915-927. (Pubitemid 32607038)
13. Fiuza SM, Gomes C, Teixeira LJ, Girao da Cruz MT, Cordeiro MN, Milhazes N, et al. Phenolic acid derivatives with potential anticancer properties - a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg Med Chem 2004; 12:3581-3589. (Pubitemid 38746860)
14. Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y, Yabu Y. Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem Biophys Res Commun 1994; 204:898-904. (Pubitemid 24344005)
15. Yoshioka K, Kataoka T, Hayashi T, Hasegawa M, Ishi Y, Hibasami H. Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines. Oncol Rep 2000; 7:1221-1223.
16. Kang MK, Kang NJ, Jang YJ, Lee KW, Lee HJ. Gallic acid induces neuronal cell death through activation of c-Jun N-terminal kinase and downregulation of Bcl-2. Ann N Y Acad Sci 2009; 1171:514-520.
17. Ji BC, Hsu WH, Yang JS, Hsia TC, Lu CC, Chiang JH, et al. Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J Agric Food Chem 2009; 57:7596-7604.
18. Su CC, Chen GW, Lin JG, Wu LT, Chung JG. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006; 26:1281-1288.
19. 0-methyl)]anilino-4-oxo-4, 5-dihydrofuran-3- carboxyla te (JOTO1007) in human cervical cancer Ca ski cells. In Vivo 2009; 23:613-619.
20. Hsu SC, Kuo CL, Lin JP, Lee JH, Lin CC, Su CC, et al. Crude extracts of Euchresta formosana radix inhibit invasion and migration of human hepatocellular carcinoma cells. Anticancer Res 2007; 27:2377-2384.
21. Kuo TC, Yang JS, Lin MW, Hsu SC, Lin JJ, Lin HJ, et al. Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappa B in cell survival. J Pharmacol Exp Ther 2009; 330:736-744.
22. Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, Chung JG. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (u PA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010; 58:2935-2942.
23. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001; 61:3194-3199. (Pubitemid 32691975)
24. Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC, et al. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. Int J Cancer 2002; 99:505-513. (Pubitemid 34461602)
25. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 1997; 137:1445-1457. (Pubitemid 27265954)
26. Kao WT, Lin CY, Lee LT, Lee PP, Hung CC, Lin YS, et al. Investigation of MMP-2 and -9 in a highly invasive A431 tumor cell sub-line selected from a Boyden chamber assay. Anticancer Res 2008; 28:2109-2120.
27. Anand-Apte B, Zetter B. Signaling mechanisms in growth factor-stimulated cell motility. Stem Cells 1997; 15:259-267. (Pubitemid 27315329)
28. Price JT, Thompson EW. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 2002; 6:217-233. (Pubitemid 34477462)
29. Fenteany G, Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 2003; 3:593-616.
30. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-336. (Pubitemid 121001258)
31. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-792. (Pubitemid 29220691)
32. Papathoma AS, Zoumpourlis V, Balmain A, Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog 2001; 31:74-82.
33. Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998; 63:295-313. (Pubitemid 128669571)
34. Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 1998; 4:3011-3016. (Pubitemid 29001475)
35. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappa B elements. Cell Growth Differ 1999; 10:353-367. (Pubitemid 29242601)
36. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435:29-34. (Pubitemid 28432009)
37. Rhee JW, Lee KW, Sohn WJ, Lee Y, Jeon OH, Kwon HJ, Kim DS. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to Cp G-oligodeoxynucleotides in RAW 264.7 cells. Mol Immunol 2007; 44:1393-1400. (Pubitemid 44415954)
38. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193. (Pubitemid 32166488)